10 results
To establish the drug drug interaction of paracetamol with propranolol and the effect of this interaction on the pharmacokinetic profile and metabolites of paracetamol.
The objective is to study the effect of beta-agonist and beta-antagonist treatment on human bone remodeling.
Primary ObjectiveTo evaluate the efficacy and safety/tolerability of UK-432,097 DPI in adults with moderate to severe COPD (GOLD stage II/III).
To assess the proportion of patients who are alive without disease progression at 6 months based on local investigator assessment per RECIST v1.1 in cohort A and cohort B 13-03-2019: new cohort added (3 cohorts now)
The goal of the present study is to investigate whether the blockade of NA-transmission by beta-antagonist propranolol reduces the common EMDR effects (reduced vividness/emotionality of emotional memories) in order to find out if NA-release (evoked…
MAIN OBJECTIVEDose escalation phase :- To determine the MTD and/or RDE of alpelisib (BYL719) in combination with everolimus, and the MTD and/or RDE of alpelisib in combination with everolimus and exemestaneDose expansion part:- To describe safety…
The aim of this study is to determine the effects of propranolol on patients* crucial fear-related memories and dental trait anxiety in those undergoing surgical removal of one of their teeth or molars. The hypotheses that are tested are that…
Primary: The primary objective is to determine whether treatment with alpelisib in combination with fulvestrant prolongs progression free survival (PFS) compared to treatment with placebo in combination with fulvestrant based on local radiological…
The purpose of the study is to determine whether treatment with alpelisib in combination with olaparib can delay the time to cancer progression compared to standard-of-care chemotherapy in participants with your type of ovarian cancer known as…
The primary objective is to determine the clinical response of propranolol monotherapy in patients with angiosarcoma. The secondary endpoint is to assess the pathologic response of propranolol monotherapy in patients with angiosarcoma.